Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases

Inflammatory Bowel Diseases

Volumn 18, Issue 11, 2012, Pages 2004-2010

  Park, Sang Hyoung ^a   Yang, Suk Kyun ^a   Lim, Young Suk ^a   Shim, Ju Hyun ^a   Yang, Dong Hoon ^a   Jung, Kee Wook ^a   Kim, Kyung Jo ^a   Ye, Byong Duk ^a   Byeon, Jeong Sik ^a   Myung, Seung Jae ^a   Kim, Jin Ho ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

chronic hepatitis B; inflammatory bowel disease; outcome; reactivation

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; MERCAPTOPURINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; ENTERITIS; FEMALE; FOLLOW UP; HEPATITIS B; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCTOCOLECTOMY; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84867577708     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22905     Document Type: Article

References (21)

1. Sands BE, Siegel CA,. Crohn's disease. In:, Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 9th ed. Philadelphia: WB Saunders; 2010: 1941-1974.
2. Xunrong L, Yan AW, Liang R, et al. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy: pathogenesis and management. Rev Med Virol. 2001; 11: 287-299.
3. Gust ID,. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut. 1996; 38 (Suppl 2): S18-23.
4. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2008; 14: 542-549.
5. Thia KT, Loftus EV Jr, Sandborn WJ, et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008; 103: 3167-3182.
6. Loras C, Gisbert JP, Minguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010; 59: 1340-1346.
7. Katsanos KH, Tsianos VE, Zois CD, et al. Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. J Crohns Colitis. 2010; 4: 450-465.
8. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998; 114: 1161-1168.
9. Yang SK, Hong WS, Min YI, et al. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. J Gastroenterol Hepatol. 2000; 15: 1037-1042.
10. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (Suppl A): 5-36.
11. Hong WS, Kim CY,. Seroepidemiology of type A and type B hepatitis in Seoul area. Korean J Intern Med. 1982; 25: 19-26.
12. Sim JG, Seo JK, Suh SJ,. Prevalence and its changes of hepatitis B viral markers from 1988 to 1993 in Korean children. J Korean Pediatr Soc. 1995; 38: 1535-1539.
13. Kwon SY, Lee CH,. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011; 17: 87-95.
14. Firpi RJ, Nelson DR,. Management of viral hepatitis in hematologic malignancies. Blood Rev. 2008; 22: 117-126.
15. Vento S, Cainelli F, Longhi MS,. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol. 2002; 3: 333.
16. Yeo W, Chan PKS, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000; 62: 299-307.
17. Lan JL, Chen YM, Hsieh TY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011; 70: 1719-1725.
18. Gisbert JP, Chaparro M, Esteve M,. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011; 33: 619-633.
19. Boxall EH, Sira J, Standish RA, et al. Natural history of hepatitis B in perinatally infected carriers. Arch Dis Child Fetal Neonatal Ed. 2004; 89: F456-460.
20. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009; 3: 47-91.
21. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010; 69: 1352-1355.